Eastman Dental Institute


Novel filling materials

Professor Anne Young, Professor Paul Ashley, Dr Wendy Xia, Professor Lambis Petridis, Dr Elaine Allan, Dr Nabih Alkhouri

Referrals of children to the Eastman Dental Hospital for tooth extraction due to caries has more than doubled in the past six years and this is the most likely reason for a child in the UK requiring a general anaesthetic. With the ban on the use of amalgam fillings in July 2018 and complexity of placement of the “white” composite alternative, referrals can only increase.


The aim of this study is therefore to develop a composite that can be placed in general dental practice directly on disease affected dentine without the need for drill or anaesthetic.

Professor Anne Young began working on this topic in 2000 funded by Schottlander dental company. From 2010 it was supported first by the Engineering and Physical Sciences Research Council (EPSRC), then by a NIHR Invention for Innovation Product Development Award and more recently by NIHR University College London Hospitals Biomedical Research Centre (BRC).

A new single step dental composite has been produced that can bond directly onto disease affected tooth structure without need for the current multiple, complex and time-consuming methods of tooth preparation. Through effective cavity sealing, it halts the growth of bacteria that start the decay process and reduces subsequent enzyme activated tooth degradation. An optimised formulation has recently been commercially manufactured, fully tested and packaged. 

Current activities

MHRA approval for a First-in-Man clinical trial with EDI SMART composite was obtained in December 2018 and the material placed for the first time in paediatric patients in January 2019*. Preliminary clinical results confirmed the novel composite can be safely placed following minimal excavation of badly decayed tooth structure in a single step. These features removed the need for anaesthetic and greatly reduced the time required for restoration placement making it highly suitable for treatment of children. 

This work will be followed by applications to undertake a larger pivotal trial to provide evidence of longer term efficacy to support CE marking. The material is to be manufactured and distributed through Davis, Schottlander and Davis.

*This first clinical trial involved composite placement in patients as a temporary filling in teeth that required extraction.

YouTube Widget Placeholderhttps://www.youtube.com/watch?v=jOc594hXB6k&feature=youtu.be


Webinar originally broadcast 20 August 2020.